PMID- 34461213
OWN - NLM
STAT- MEDLINE
DCOM- 20220311
LR  - 20240102
IS  - 1873-3441 (Electronic)
IS  - 0939-6411 (Linking)
VI  - 169
DP  - 2021 Dec
TI  - Successively triggered Rod-shaped protocells for enhanced tumor 
      Chemo-Photothermal therapy.
PG  - 1-11
LID - S0939-6411(21)00222-8 [pii]
LID - 10.1016/j.ejpb.2021.08.012 [doi]
AB  - Abundant existence of extracellular matrix biological hydrogels in solid tumors 
      precludes most therapeutics to arrive at intracellular target sites, which is 
      probably one of the threatened reasons of pancreatic ductal adenocarcinoma (PDAC) 
      for public health. In this study, we designed a rod-shaped protocell nanoparticle 
      loading with doxorubicin hydrochloride (Dox) and indocyanine green (ICG), denoted 
      as Dox/ICG-RsPNs, for enhanced chemo-photothermal PDAC treatment. The enhanced 
      therapeutic efficacy was achieved by successively enhancing penetration across 
      matrix hydrogels, endocytosis, increasing local temperature under laser 
      irradiation and hyperthermia-triggered Dox release to nucleus. We found that 
      RsPNs with rod shape could easily penetrate across matrix hydrogel, exerting 
      excellent tumor accumulation. Then RsPNs was internalized effectively by BxPC-3 
      cells via a caveolin-mediated endocytosis pathway. In addition, ICG endowed the 
      Dox/ICG-RsPNs with photothermal effect and the photothermal conversion efficiency 
      was calculated for 16.2%. Under irradiation, a great number of Dox transported to 
      the nucleus via hyperthermia-induced release. Furthermore, we found that the 
      relative tumor volume of Dox/ICG-RsPNs was merely 1.37 under irradiation at the 
      end of pharmacodynamic studies, which was significantly lower than that of other 
      groups. These findings will provide a promise on the rational design of drug 
      delivery system for effective chemo-photothermal combination therapy to treat 
      PDAC.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Zhang, Wei
AU  - Zhang W
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
FAU - Chen, Lu
AU  - Chen L
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
FAU - Cui, Mingshu
AU  - Cui M
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
FAU - Xie, Luyao
AU  - Xie L
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
FAU - Xi, Ziyue
AU  - Xi Z
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
FAU - Wang, Yuwen
AU  - Wang Y
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
FAU - Shen, Xiaohan
AU  - Shen X
AD  - Affiliated Cixi Hospital, Wenzhou Medical University, Cixi 315300, China.
FAU - Xu, Lu
AU  - Xu L
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China. 
      Electronic address: xulu@syphu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20210827
PL  - Netherlands
TA  - Eur J Pharm Biopharm
JT  - European journal of pharmaceutics and biopharmaceutics : official journal of 
      Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JID - 9109778
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Coloring Agents)
RN  - 0 (Nanoparticle Drug Delivery System)
RN  - 80168379AG (Doxorubicin)
RN  - IX6J1063HV (Indocyanine Green)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/pharmacology
MH  - Artificial Cells
MH  - Biological Availability
MH  - Cell Line, Tumor
MH  - Coloring Agents/pharmacology
MH  - Doxorubicin/*pharmacology
MH  - Drug Therapy/*methods
MH  - Extracellular Matrix
MH  - Humans
MH  - Hyperthermia, Induced/*methods
MH  - Indocyanine Green/*pharmacology
MH  - Mice
MH  - Nanoparticle Drug Delivery System/pharmacology
MH  - Pancreatic Neoplasms
MH  - Photothermal Therapy/*methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Chemo-photothermal therapy
OT  - Matrix biological hydrogels
OT  - Rod-shaped protocells
OT  - Successive delivery process
OT  - Tumor penetration
EDAT- 2021/08/31 06:00
MHDA- 2022/03/12 06:00
CRDT- 2021/08/30 20:13
PHST- 2021/06/05 00:00 [received]
PHST- 2021/08/11 00:00 [revised]
PHST- 2021/08/23 00:00 [accepted]
PHST- 2021/08/31 06:00 [pubmed]
PHST- 2022/03/12 06:00 [medline]
PHST- 2021/08/30 20:13 [entrez]
AID - S0939-6411(21)00222-8 [pii]
AID - 10.1016/j.ejpb.2021.08.012 [doi]
PST - ppublish
SO  - Eur J Pharm Biopharm. 2021 Dec;169:1-11. doi: 10.1016/j.ejpb.2021.08.012. Epub 
      2021 Aug 27.